Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Current success of immunotherapy in cancer has drawn attention to the subsets of TH cells
in the tumor which are critical for activation of anti-tumor response either directly by …

Trogocytosis is an active process that transfers surface material from targeted to effector
cells. Using multiple in vivo tumor models and clinical data, we report that chimeric antigen …

Abstract CD4+ T cells and CD4+ chimeric antigen receptor (CAR) T cells display highly
variable antitumor activity in preclinical models and in patients; however, the mechanisms …

Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the
therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen …

Chimeric antigen receptor (CAR) T cell therapy relies on the activity of a large pool of tumor-
targeting cytotoxic effectors. Whether CAR T cells act autonomously or require interactions …

Adoptive cell therapy with T cells reprogrammed to express chimeric antigen receptors (CAR-
T cells) has been highly successful in patients with hematological neoplasms. However, its …

Corticosteroids are commonly used for the management of severe toxicities associated with
chimeric antigen receptor (CAR) T-cell therapy. However, it remains unclear whether their …

This review is focused on different subsets of T cells: CD4 and CD8, memory and effector
functions, and their role in CAR-T therapy––a cellular adoptive immunotherapy with T cells …

By providing spatial, molecular and morphological data over time, live-cell imaging can
provide a deeper understanding of the cellular and signalling events that determine cancer …